search
Back to results

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years (CanBenefitII)

Primary Purpose

Lung Neoplasm Malignant, Mesothelioma; Lung

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Tailored nutrition and physical activity programme
Sponsored by
University of Hull
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Lung Neoplasm Malignant focused on measuring Physical Activity, Nutrition, Feasibility RCT, Lung cancer, Older adults

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. age ≥65 years,
  2. diagnosed with stage III or IV lung cancer or mesothelioma,
  3. starting a new line of systemic anti-cancer treatment,
  4. willing and able to complete study measures and be randomised
  5. able to provide informed written or verbal witnessed consent

Exclusion Criteria:

  1. Patients receiving radical chemoradiation therapy (potentially curative and require parental feeding)
  2. Have had more than one dose of new treatment.
  3. Unstable acute condition (e.g., acute infection, severe uncontrolled symptoms) or
  4. Underlying chronic condition (e.g., severe arthritis or dementia) that would impact study compliance.
  5. Unable to provide written or verbal consent.
  6. Insufficient English for consent and study procedures and appropriate interpretation unavailable

Sites / Locations

  • Hull University Teaching Hospitals NHS Trust
  • York and Scarborough Teaching Hospitals NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention arm

Usual care arm

Arm Description

12 weeks home based tailored nutrition and physical activity (PA) programme Participants will have an appointment (face-to-face if possible) with the study physiotherapist and dietitian for delivery of the PA (including breathlessness management) and nutrition intervention components. Participants will receive study equipment at these appointments (or by post) including paper-based tracking diary, resistance bands for strength exercises, a Fitbit activity monitor to track steps and aerobic activity during the study period, nutritional supplements (if prescribed), and printed study materials (if preferred over pdf emails; e.g. cooking tips, recipes). A video/telephone follow-up call (10-15 minutes) will be conducted by the research team with the participant at weeks 2,3,4,5 and 6 and then at weeks 8,10 and 12 to review and adjust their programme (with input from the physiotherapist and dietitian if required).

The usual cancer care will include usual patient management and care prior, during and after cancer treatment - medication, symptom control, cancer advice and support from routine medical and nursing input with access to Allied Health Professionals (AHPs) such as physiotherapists and dietitians as clinically indicated. As part of this, it is common for older adults with cancer to be prescribed high protein supplementation. Control participants will receive a general information leaflet regarding activity and nutrition.

Outcomes

Primary Outcome Measures

Recruitment Rate
The Recruitment Rate will be assessed by the number of eligible patients approached vs the number of eligible patients consent for the study, providing a number of non-participations. This will be gathered as an aspect of feasibility.
Retention Rate
Retention rate will be examined via the number of those who consent to the study compared to the number of those who complete the study.
Secondary outcome data completion rate
Assessed by the total number of missing data from the total list of secondary outcomes
Rate of Intervention Completion
The percentage of exercises prescribed to the participants compared to the number of those completed.
Incidence of adverse effects and injuries related to the intervention
Assessed by the number and rate of participant recorded adverse effects and injuries related to the intervention
Incidence of adverse events not related to the intervention
The number of adverse events exhibited by the participants will be recorded with an associated grade (where relevant). A example list of adverse events are given below: Constipation Nausea Vomiting Diarrhoea Skin Rash

Secondary Outcome Measures

Free-living daily activity
Accelerometer; the activpal4 micro units (activpal4; https://www.palt.com/pals/)
Australian Karnofsky Performance Scale (AKPS)
Single score from 10 to 100 (a higher score indicates better performance status).
Rockwood Frailty Index, a 7-point Clinical Frailty Scale
1 = very fit, and 7= severely frail.
Short Physical Performance Battery (SPBB)
Combines standing balance, 4 metre gait speed, and timed sit-to-stands to assess lower extremity function in older people
Grip strength
Maximum force/tension (kg) in the forearm muscles using a handheld dynamometer.
Bioelectrical impedance
Tanita body composition monitor and weight scale, a simple, non-invasive technique for measuring body composition in people with cancer
Weight (kg)
Tanita body composition monitor and weight scale
Patient-Generated Subjective Global Assessment (PG-SGA)
Assessment of nutritional status for people with cancer (scores from 0 - ≥9; 2-3 indicating need for basic nutrition intervention, 4-8 requiring dietetic intervention, and scores ≥9 indicating critical need for symptom management and nutritional intervention).
Community Healthy Activities Model Program for Seniors (CHAMPS)
Self-report total physical activity questionnaire designed to estimate weekly frequency of participation and energy expenditure in physical activities.
Integrated Patient Outcome Scale (IPOS)
measure of symptom burden with 20 items: one free-text question about main problems and concerns, 17 items on physical, psychological, spiritual problems, communication needs including with family, and practical support, scored on a 5-point Likert-type scale from 0 (best) to 4 (worst)
Client Service Receipt Inventory
Validated questionnaire designed to collect information on service utilisation, income, accommodation and other cost-related variables
EuroQol-5 Dimensions-5 Levels
The EQ-5D-5L is a generic health-related quality-of-life instrument with a descriptive system that comprises five dimensions (1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort, and 5) anxiety/depression), each of which has five levels of severity (given in statement form). Participants select a statement under each of the five dimensions which best suits their current state. In addition, the respiratory bolt on dimension for the EQ-5D-5L. For each dimension, lower scores indicate fewer problems in that domain (e.g. a score of 1 in mobility means no issues with mobility).
EuroQol-Visual Analogue Scale
The EQ-VAS is a self-report measure of overall health using a vertical visual analogue scale, ranging from 0 labelled as "worst possible" to 100 labelled as "best possible" health. Participants are then asked to write this number in a dedicated box.
Days alive and out of hospital
Hospital admission (number of days) since starting the programme
Treatment completion rate
Dose of cancer therapy received (percentage of dose received/dose prescribed) Treatment delay (days delayed)
Infection rate
Assessed by the number of episodes requiring antibiotics (oral/IV) Number of episodes requiring hospital admission (number of days)
Treatment toxicity
Cancer treatment-related toxicity (CTCAE v 5)
Height
measured in cm with a Seneca Stadiometer

Full Information

First Posted
May 12, 2022
Last Updated
September 7, 2023
Sponsor
University of Hull
search

1. Study Identification

Unique Protocol Identification Number
NCT05404022
Brief Title
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years
Acronym
CanBenefitII
Official Title
Cancer Behavioural Nutrition and Exercise Feasibility Trial - Phase II Randomised Controlled Trial Among Older Adults With Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
June 20, 2022 (Actual)
Primary Completion Date
September 1, 2023 (Actual)
Study Completion Date
September 1, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Hull

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
People with cancer affecting the lungs tend to be older and frailer compared to people with other cancers. As a result, they may have poorer quality of life and are less able to tolerate treatments for their cancer, such as chemotherapy. Research to date show that nutrition and physical activity support helps people with cancer, but not many older people are included in these studies. The investigators want to develop and test a nutrition and activity programme for older people with lung cancer that can be tailored to each patient to help them have the best possible quality of life from the moment they start a new line of cancer treatment. The research team has conducted the development work to find which nutrition and activity programmes are best for this patient group and how best to deliver the programme by looking at prior studies and talking to patients and carers as well as health care providers. The next step is to test the developed programme in a small pilot study, to i) see if it is possible and acceptable (to patients, families, and staff) to deliver and ii) see if it helps patients have and cope with anti-cancer treatments and improve patient quality of life.
Detailed Description
BACKGROUND Lung cancer is the third most commonly diagnosed cancer in the UK and most common in Yorkshire. It is also the most common cause of cancer death in UK. People with lung cancer are often older with co-morbidities and frailty resulting in a poor prognosis - especially if they are unfit for treatment. Approximately half of new cancer cases in UK are people aged 65 and over. Frailty, with sarcopenia (age-related decline in skeletal muscle), cachexia (disease-related body wasting) and nutritional deficiencies, may limit chemotherapy options, reduce treatment effectiveness, result in dose reductions and poor treatment completion rates. Physical activity (PA) interventions benefit people living with or beyond cancer by improving physical function and quality of life (QoL) during and after cancer treatment. Reduced physical function is associated with higher mortality in older adults with cancer.PA improves treatment completion, treatment recovery, survival rates and reduces healthcare use. Emerging work indicates that activity improves immune function in older adults with cancer; important as better immune function has been linked to improved treatment outcomes. A recent meta-analysis shows reduced risk of cancer-specific and all-cause mortality for those more active among people with lung cancer. Weight loss and poor nutrition may prevent patients from completing cancer treatments and increase the risk and severity of treatment toxicity. In those receiving chemotherapy, better nutritional status is associated with improved survival and, in lung cancer patients undergoing chemotherapy, better QoL. Cancer treatments can cause many side-effects that impact eating, including; fatigue, nausea, vomiting, dry mouth/oral candidiasis, disordered taste, ill-fitting dentures, diarrhoea, constipation, oesophagitis, early satiety and poor appetite; all difficult for patients to self-manage. Nutritional interventions, including dietary counselling and nutrition advice, improve patient wellbeing and rate of treatment completion. Despite the urgent need for improvements in survival outcomes for older people with lung cancer, a significant evidence gap remains regarding nutrition. This team's systematic review highlighted the lack of PA and nutrition programme research for older adults living with and beyond cancer. Studies including older adults often focus on prostate cancer, generally a group with a better prognosis. Therefore, many older adults with other cancers, such as lung cancer (only one study in our review), are not represented. Qualitative interviews with patients, carers, and clinicians in Hull (with experience of lung cancer) confirmed poor access to, but support for and interest in, wellbeing interventions but only if tailored to their needs - including management of activity-related breathlessness. A tailored wellbeing intervention, designed to improve or maintain physical function via lifestyle behaviours, may decrease older adults with lung cancer needing dose reductions. Dose intensity is significantly associated with mortality among people receiving treatment for lung cancer. By maintaining physical function/nutrition, people can tolerate more treatment with subsequent better overall survival. This could be very significant among people diagnosed with lung cancer, a cancer with generally poor prognosis. Therefore, the aim of this study is to investigate the feasibility and acceptability of conducting a future definitive trial of a tailored wellbeing (nutrition and activity) programme for older adults with lung cancers who are starting a new line of systemic anticancer therapy. AIMS AND OBJECTIVES Primary aim/objective To determine the feasibility and acceptability of a tailored wellbeing (nutrition and activity) programme for older adults with lung cancer beginning a new line of systemic anti-cancer therapy in terms of recruitment, intervention delivery, appropriateness of candidate primary outcomes, estimated sample size for a future phase III trial. Secondary aims/objectives To assess data quality QoL* and QoL adjusted days alive out of hospital* treatment dose intensity* episodes of infection fatigue functional status To assess participant/clinician acceptability and experience *candidate primary outcomes for subsequent trial

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Neoplasm Malignant, Mesothelioma; Lung
Keywords
Physical Activity, Nutrition, Feasibility RCT, Lung cancer, Older adults

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm
Arm Type
Experimental
Arm Description
12 weeks home based tailored nutrition and physical activity (PA) programme Participants will have an appointment (face-to-face if possible) with the study physiotherapist and dietitian for delivery of the PA (including breathlessness management) and nutrition intervention components. Participants will receive study equipment at these appointments (or by post) including paper-based tracking diary, resistance bands for strength exercises, a Fitbit activity monitor to track steps and aerobic activity during the study period, nutritional supplements (if prescribed), and printed study materials (if preferred over pdf emails; e.g. cooking tips, recipes). A video/telephone follow-up call (10-15 minutes) will be conducted by the research team with the participant at weeks 2,3,4,5 and 6 and then at weeks 8,10 and 12 to review and adjust their programme (with input from the physiotherapist and dietitian if required).
Arm Title
Usual care arm
Arm Type
No Intervention
Arm Description
The usual cancer care will include usual patient management and care prior, during and after cancer treatment - medication, symptom control, cancer advice and support from routine medical and nursing input with access to Allied Health Professionals (AHPs) such as physiotherapists and dietitians as clinically indicated. As part of this, it is common for older adults with cancer to be prescribed high protein supplementation. Control participants will receive a general information leaflet regarding activity and nutrition.
Intervention Type
Other
Intervention Name(s)
Tailored nutrition and physical activity programme
Intervention Description
Physical activity prescriptions will follow recent guidance for people with cancer and the FITT principles: Frequency (weekly sessions), Intensity (how hard), Time (session duration), and Type. Programme content, duration, and intensity will be tailored for comorbidities and other limitations. Nutrition prescription may include any or all of the following: Information on side-effects that may affect eating and their mitigation Feedback on physical measures (weight loss) in relation to nutrition and treatment outcomes Feedback on assessment of food intake and how to improve a Macmillan booklet: advice on eating and maintaining weight throughout cancer treatments. a recipe book "Making the most of every bite" tailored oral nutritional support, including use of high calorie/protein nutrition supplementation, or other macro and micronutrient supplementation as required
Primary Outcome Measure Information:
Title
Recruitment Rate
Description
The Recruitment Rate will be assessed by the number of eligible patients approached vs the number of eligible patients consent for the study, providing a number of non-participations. This will be gathered as an aspect of feasibility.
Time Frame
24 weeks
Title
Retention Rate
Description
Retention rate will be examined via the number of those who consent to the study compared to the number of those who complete the study.
Time Frame
24 weeks
Title
Secondary outcome data completion rate
Description
Assessed by the total number of missing data from the total list of secondary outcomes
Time Frame
24 weeks
Title
Rate of Intervention Completion
Description
The percentage of exercises prescribed to the participants compared to the number of those completed.
Time Frame
12 weeks
Title
Incidence of adverse effects and injuries related to the intervention
Description
Assessed by the number and rate of participant recorded adverse effects and injuries related to the intervention
Time Frame
Week 1 to week 12
Title
Incidence of adverse events not related to the intervention
Description
The number of adverse events exhibited by the participants will be recorded with an associated grade (where relevant). A example list of adverse events are given below: Constipation Nausea Vomiting Diarrhoea Skin Rash
Time Frame
Week 1 to week 52
Secondary Outcome Measure Information:
Title
Free-living daily activity
Description
Accelerometer; the activpal4 micro units (activpal4; https://www.palt.com/pals/)
Time Frame
Baseline, 24 weeks
Title
Australian Karnofsky Performance Scale (AKPS)
Description
Single score from 10 to 100 (a higher score indicates better performance status).
Time Frame
baseline, 12 and 24 weeks
Title
Rockwood Frailty Index, a 7-point Clinical Frailty Scale
Description
1 = very fit, and 7= severely frail.
Time Frame
baseline, 12 and 24 weeks
Title
Short Physical Performance Battery (SPBB)
Description
Combines standing balance, 4 metre gait speed, and timed sit-to-stands to assess lower extremity function in older people
Time Frame
baseline, 12 and 24 weeks
Title
Grip strength
Description
Maximum force/tension (kg) in the forearm muscles using a handheld dynamometer.
Time Frame
baseline, 12 and 24 weeks
Title
Bioelectrical impedance
Description
Tanita body composition monitor and weight scale, a simple, non-invasive technique for measuring body composition in people with cancer
Time Frame
baseline, 12 and 24 weeks
Title
Weight (kg)
Description
Tanita body composition monitor and weight scale
Time Frame
baseline, 12 and 24 weeks
Title
Patient-Generated Subjective Global Assessment (PG-SGA)
Description
Assessment of nutritional status for people with cancer (scores from 0 - ≥9; 2-3 indicating need for basic nutrition intervention, 4-8 requiring dietetic intervention, and scores ≥9 indicating critical need for symptom management and nutritional intervention).
Time Frame
baseline and after 6, 12, and 24 weeks
Title
Community Healthy Activities Model Program for Seniors (CHAMPS)
Description
Self-report total physical activity questionnaire designed to estimate weekly frequency of participation and energy expenditure in physical activities.
Time Frame
baseline and after 6, 12, and 24 weeks
Title
Integrated Patient Outcome Scale (IPOS)
Description
measure of symptom burden with 20 items: one free-text question about main problems and concerns, 17 items on physical, psychological, spiritual problems, communication needs including with family, and practical support, scored on a 5-point Likert-type scale from 0 (best) to 4 (worst)
Time Frame
baseline and after 6, 12, and 24 weeks
Title
Client Service Receipt Inventory
Description
Validated questionnaire designed to collect information on service utilisation, income, accommodation and other cost-related variables
Time Frame
baseline and after 6, 12, and 24 weeks
Title
EuroQol-5 Dimensions-5 Levels
Description
The EQ-5D-5L is a generic health-related quality-of-life instrument with a descriptive system that comprises five dimensions (1) mobility, 2) self-care, 3) usual activities, 4) pain/discomfort, and 5) anxiety/depression), each of which has five levels of severity (given in statement form). Participants select a statement under each of the five dimensions which best suits their current state. In addition, the respiratory bolt on dimension for the EQ-5D-5L. For each dimension, lower scores indicate fewer problems in that domain (e.g. a score of 1 in mobility means no issues with mobility).
Time Frame
baseline and after 6, 12, and 24 weeks
Title
EuroQol-Visual Analogue Scale
Description
The EQ-VAS is a self-report measure of overall health using a vertical visual analogue scale, ranging from 0 labelled as "worst possible" to 100 labelled as "best possible" health. Participants are then asked to write this number in a dedicated box.
Time Frame
baseline and after 6, 12, and 24 weeks
Title
Days alive and out of hospital
Description
Hospital admission (number of days) since starting the programme
Time Frame
baseline, and after 6, 12, and 24 weeks
Title
Treatment completion rate
Description
Dose of cancer therapy received (percentage of dose received/dose prescribed) Treatment delay (days delayed)
Time Frame
baseline, and after 6, 12, and 24 weeks
Title
Infection rate
Description
Assessed by the number of episodes requiring antibiotics (oral/IV) Number of episodes requiring hospital admission (number of days)
Time Frame
baseline, and after 6, 12, and 24 weeks
Title
Treatment toxicity
Description
Cancer treatment-related toxicity (CTCAE v 5)
Time Frame
baseline, and after 6, 12, and 24 weeks
Title
Height
Description
measured in cm with a Seneca Stadiometer
Time Frame
baseline, 12 and 24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: age ≥65 years, diagnosed with stage III or IV lung cancer or mesothelioma, starting a new line of systemic anti-cancer treatment, willing and able to complete study measures and be randomised able to provide informed written or verbal witnessed consent Exclusion Criteria: Patients receiving radical chemoradiation therapy (potentially curative and require parental feeding) Have had more than one dose of new treatment. Unstable acute condition (e.g., acute infection, severe uncontrolled symptoms) or Underlying chronic condition (e.g., severe arthritis or dementia) that would impact study compliance. Unable to provide written or verbal consent. Insufficient English for consent and study procedures and appropriate interpretation unavailable
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cynthia Forbes, PhD
Organizational Affiliation
Hull York Medical School, University of Hull
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hull University Teaching Hospitals NHS Trust
City
Hull
State/Province
Yorkshire
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Facility Name
York and Scarborough Teaching Hospitals NHS Trust
City
York
State/Province
Yorkshire
ZIP/Postal Code
YO31 8HE
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33059998
Citation
Swan F, Chen H, Forbes CC, Johnson MJ, Lind M. CANcer BEhavioural nutrition and exercise feasibility trial (CanBenefit); phase I qualitative interview findings. J Geriatr Oncol. 2021 May;12(4):641-648. doi: 10.1016/j.jgo.2020.09.026. Epub 2020 Oct 12.
Results Reference
result
PubMed Identifier
32328828
Citation
Forbes CC, Swan F, Greenley SL, Lind M, Johnson MJ. Physical activity and nutrition interventions for older adults with cancer: a systematic review. J Cancer Surviv. 2020 Oct;14(5):689-711. doi: 10.1007/s11764-020-00883-x. Epub 2020 Apr 24.
Results Reference
result

Learn more about this trial

Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years

We'll reach out to this number within 24 hrs